跳至主要内容
临床试验/NCT02487693
NCT02487693进行中(未招募)2 期

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma

The First People's Hospital of Changzhou0 个研究点目标入组 50 人开始时间: 2015年7月最近更新:
适应症

试验速览

阶段
2 期
状态
进行中(未招募)
入组人数
50
主要终点
Recurrence-free survival

研究概览

简要总结

The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with ovarian carcinoma.

详细描述

The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong survival of patients with ovarian carcinoma.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
30 Years 至 70 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • patients diagnosed with FIGO stage II ovarian carcinoma;
  • cytoreductive surgery performed and 6 courses of platinum-based chemotherapy completed;
  • medical records maintain comprehensive data on treatment and follow-up;
  • no history of previous malignancies.

排除标准

  • neoadjuvant chemotherapy applied;
  • less than 6 courses of chemotherapy or more than 6 courses of chemotherapy completed;
  • medical records maintain incomplete data on treatment or follow-up;
  • history of previous malignancy.

结局指标

主要结局

Recurrence-free survival

时间窗: 1 year

Recurrence-free survival (RFS) was defined as the time from the date of RFA to the date of recurrence or the date of the last follow-up.

次要结局

  • Adverse events(4 weeks)

研究者

申办方类型
Other
责任方
Sponsor

相似试验